-
Framework for Brain-Derived Dimensions of Psychopathology. JAMA Psychiatry (IF 22.5) Pub Date : 2025-06-18 Tristram A Lett,Nilakshi Vaidya,Tianye Jia,Elli Polemiti,Tobias Banaschewski,Arun L W Bokde,Herta Flor,Antoine Grigis,Hugh Garavan,Penny Gowland,Andreas Heinz,Rüdiger Brühl,Jean-Luc Martinot,Marie-Laure Paillère Martinot,Eric Artiges,Frauke Nees,Dimitri Papadopoulos Orfanos,Herve Lemaitre,Tomáš Paus,Luise Poustka,Argyris Stringaris,Lea Waller,Zuo Zhang,Jeanne Winterer,Yuning Zhang,Michael N Smolka
Importance Psychiatric diagnoses are not defined by neurobiological measures hindering the development of therapies targeting mechanisms underlying mental illness. Research confined to diagnostic boundaries yields heterogeneous biological results, whereas transdiagnostic studies often investigate individual symptoms in isolation. Objective To develop a framework that groups clinical symptoms compatible
-
Sweetened Beverages and Incident All-Cause Dementia Among Older Adults JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-18 Hui Chen, Yihong Ding, Klodian Dhana, Puja Agarwal, Todd Beck, Kumar B. Rajan, Debora Melo van Lent, Yuan Ma, Geng Zong, Kjetil Bjornevik, Changzheng Yuan
ImportanceIntake of sweetened beverages, including sugar-sweetened beverages (SSB) and artificially sweetened beverages (ASB), has been linked to multiple health outcomes, but their associations with dementia risk among older adults are unclear.ObjectiveTo assess whether the consumption of SSB and ASB is associated with the risk of all-cause dementia in older adults.Design, Setting, and ParticipantsThis
-
Rescheduling Cannabis—Medicine or Politics? JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-11 Bertha K. Madras, Paul J. Larkin
ImportanceIn 2023, the US Department of Health and Human Services (HHS) issued a letter to the administrator of the Drug Enforcement Administration (DEA) recommending rescheduling of cannabis (marijuana) from Schedule I to Schedule III under the Controlled Substances Act (CSA). This recommendation marked a significant departure from previous, consistent, and long-standing federal decisions on cannabis
-
Cannabis Withdrawal and Psychiatric Intensive Care JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-11 Aliyah Malik, Hitesh Shetty, Dominic Oliver, Thomas J. Reilly, Marta Di Forti, Philip McGuire, Edward Chesney
ImportanceCannabis use is common in people with severe mental illness and its adverse effects on outcomes are well established. However, adverse outcomes may also result from cannabis withdrawal syndrome (CWS). CWS includes symptoms such as agitation, irritability, and aggression, and typically peaks after 3 to 5 days of abstinence.ObjectiveTo assess whether cannabis use prior to admission is associated
-
Differential Associations of Dopamine and Serotonin With Reward and Punishment Processes in Humans JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-11 Anahit Mkrtchian, Zeguo Qiu, Yaniv Abir, Tore Erdmann, Quentin Dercon, Terezie Sedlinska, Michael Browning, Harry Costello, Quentin J. M. Huys
ImportanceMechanistic biomarkers for guiding treatment selection require selective sensitivity to specific pharmacological interventions. Reinforcement learning processes show potential, but there have been conflicting and sometimes inconsistent reports on how dopamine and serotonin—2 key targets in treating common mental illnesses—affect reinforcement learning in humans.ObjectiveTo perform a meta-analysis
-
Simvastatin as Add-On Treatment to Escitalopram in Patients With Major Depression and Obesity JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-04 Christian Otte, Woo Ri Chae, Deniz Yildirim Dogan, Dominique Piber, Stefan Roepke, An Bin Cho, Samuel Trumm, Michael Kaczmarczyk, Jelena Brasanac, Katja Wingenfeld, Stefanie Koglin, Johannes Wieditz, Klaus Junghanns, Michael Lucht, David Prvulovic, Tillmann H. C. Krüger, Jan Terock, Moritz Haaf, Tobias Hofmann, Nicole Mauche, Jan Philipp Klein, Hans Jörgen Grabe, Andreas Reif, Kai G. Kahl, Deborah
ImportanceMajor depressive disorder (MDD) and obesity are common noncommunicable disorders associated with substantial disease burden, which frequently occur comorbidly. Intriguingly, converging lines of evidence from animal models and genetic and observational studies have suggested a biological link between obesity, metabolic syndrome, and depression. Several small randomized clinical trials (RCTs)
-
FDA Eliminates the Clozapine REMS—What Comes Next? JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-04 Deanna L. Kelly, John M. Kane, Raymond C. Love, Robert O. Cotes
This Viewpoint provides suggestions to address challenges after elimination of the Clozapine Risk Evaluation and Mitigation Strategies (REMS) system by the US Food and Drug Administration (FDA).
-
Symptom Provocation and Clinical Response to Transcranial Magnetic Stimulation JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-04 Daniel Bello, Megan Jones, Ishaan Gadiyar, Laura Artim, Sophia H. Blyth, Roscoe O. Brady, Simon Vandekar, Heather Burrell Ward
ImportanceTranscranial magnetic stimulation (TMS), a form of noninvasive brain stimulation used to treat major depressive disorder, obsessive-compulsive disorder (OCD), and nicotine dependence, has well-established state-dependent effects on brain circuitry. However, a major question for TMS remains: does brain state affect clinical response?ObjectiveTo quantify the association between symptom provocation
-
Anorexia Nervosa—Facts, Frustrations, and the Future JAMA Psychiatry (IF 17.1) Pub Date : 2025-06-04 Andrea Phillipou, Ulrike Schmidt, Erica Neill, Stephanie Miles, Patrick McGorry, Kamryn T. Eddy
ImportanceAnorexia nervosa is a prevalent psychiatric illness associated with exceptionally poor outcomes, including high rates of morbidity and premature mortality. Current evidence-based treatments for anorexia nervosa were developed several decades ago and have limited efficacy. The anorexia nervosa field—and the eating disorders field more broadly—has yet to make significant scientific breakthroughs
-
Physician Suicide and Associated Features-What Defines a Physician? JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-28 Flora Lum
-
Dry EEG-From Laboratory to Living Room. JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-28 Mohammad S E Sendi
-
Physician Suicide and Associated Features-What Defines a Physician?-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-28 Hirsh Makhija,Judy E Davidson,Sidney Zisook
-
Childhood Maternal Warmth, Social Safety Schemas, and Adolescent Mental and Physical Health JAMA Psychiatry (IF 17.1) Pub Date : 2025-05-28 Jenna Alley, Dimitris I. Tsomokos, Summer Mengelkoch, George M. Slavich
ImportanceAlthough early maternal warmth strongly predicts adolescent health, questions remain about the biopsychosocial mechanisms underlying this association.ObjectiveTo understand how maternal warmth at 3 years of age shapes adolescent social safety schemas at 14 years of age and physical and mental health at 17 years of age.Design, Setting, and ParticipantsThe Millennium Cohort Study tracks approximately
-
Private Equity Among US Psychiatric Hospitals JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-21 Morgan C. Shields, Yuanyuan Yang, Susan H. Busch
ImportancePrivate equity (PE) ownership in health care has increased, but evidence for its association with health care quality is mixed. Moreover, there is no evidence regarding inpatient psychiatric hospitals, despite considerable patient vulnerabilities.ObjectiveTo describe trends in PE ownership of psychiatric hospitals from 2013 through 2021 and the cross-sectional association between PE ownership
-
Loss of PTSD Diagnosis in Response to Evidence-Based Treatments JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-21 Tiffany Milligan, Derek Smolenski, Jose Lara-Ruiz, Marija S. Kelber
ImportanceIn recent decades, evidence-based psychotherapies to treat posttraumatic stress disorder (PTSD) have been developed with robust evidence bases. However, efficacy observed in clinical trials is not always directly applicable to clinical practice.ObjectiveTo estimate the percentage of patients in both military and veteran (hereafter milvet) and nonmilvet populations that lose their PTSD diagnosis
-
Local Anesthetics Adulterating the Illicit Fentanyl Supply JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-21 Joseph J. Palamar, Joshua S. DeBord, Alex J. Krotulski, Bruce A. Goldberger
This Viewpoint examines the use of local anesthetics to adulterate synthetic opioids, particularly illicitly manufactured fentanyl, and the dangers associated with exposure to these drugs.
-
Purposeful Drug Repurposing JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-14 Peter Nagele, Charles R. Conway, Charles F. Zorumski
This Viewpoint discusses a proposal to identify candidates for drug repurposing and allocate US Food and Drug Administration funds to cover the cost of evaluating and approving such drugs for their novel indications.
-
Health Outcomes of Discontinuing Antipsychotics After Hospitalization in Older Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-14 Chun-Ting Yang, James M. Wilkins, Elyse DiCesare, Kevin T. Pritchard, Qiaoxi Chen, Yichi Zhang, Dae Hyun Kim, Kueiyu Joshua Lin
ImportanceAmong hospitalized older adults, prolonged use of antipsychotic medications (APMs) following hospital discharge may increase the risk of APM-associated adverse events. There are limited data on whether early discontinuation of APMs is associated with reduced adverse clinical outcomes compared with APM continuation after discharge.ObjectiveTo compare clinical outcomes between discontinuation
-
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-14 Aureliane C. S. Pierret, Yuya Mizuno, Pippa Saunders, Eshaya Lim, Riccardo De Giorgi, Oliver D. Howes, Robert A. McCutcheon, Barbara McGowan, Piya Sen Gupta, Daniel Smith, Khalida Ismail, Toby Pillinger
ImportancePeople with obesity and diabetes have poorer psychiatric and cognitive outcomes and lower quality of life (QOL) compared with those without. Glucagon-like peptide 1 receptor agonists (GLP1-RAs) are treatments for diabetes and obesity that may also influence psychiatric outcomes.ObjectiveTo conduct a meta-analysis of randomized placebo-controlled trials to evaluate psychiatric, cognitive,
-
Psychiatric Prognosis Following Index Suicide Attempts in Early Adolescents JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-14 Tanner J. Bommersbach, Grace Johnson, Vanessa K. Pazdernik, J. Michael Bostwick, Alastair J. S. McKean
ImportanceThe rates of suicide and suicide attempts are rising precipitously among early adolescents aged 10 to 14 years in the US. While suicide attempts in this age group are more common and associated with lower lethality than in older age groups, very little is known about these individuals’ long-term social and psychiatric outcomes.ObjectivesTo examine the adult outcomes of individuals making
-
Genetic Architecture and Risk of Childhood Maltreatment Across 5 Psychiatric Diagnoses. JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-09 Trine Tollerup Nielsen,Paraskevi Bali,Jakob Grove,Christina Mohr-Jensen,Thomas Werge,Søren Dalsgaard,Anders D Børglum,Edmund Sonuga-Barke,Helen Minnis,Ditte Demontis,,Elizabeth C Corfield,Ludger Tbartz van Elst,Manuel Mattheisen,Melanie M de Wit,Mohammed Jashim Uddin,Richard J L Anney,Stephen W Scherer,Thomas Bourgeron,Tinca J C Polderman
Importance Childhood maltreatment (CM) is associated with psychiatric disorders. The underlying mechanisms are complex and involve genetics. Objective To investigate the polygenic architecture of CM-exposed individuals across psychiatric conditions and if genetics modulates absolute CM risk in the presence of high-impact risk factors such as parental psychiatric diagnoses. Design, Setting, and Participants
-
Estimating Treatment Effects From Observational Data-Calling It a Target Trial Does Not Make It One. JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-07 Krista F Huybrechts,Sonia Hernández-Díaz
-
Reporting and Representation of Race and Ethnicity in Clinical Trials of Pharmacotherapy for Mental Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-07 Alessio Bellato, Joaquim Raduà, Antoine Stocker, Maude-Sophie Lockman, Anusha Lall, Vishnie Ravisankar, Sonia Obiokafor, Emma Machell, Sahar Haq, Dalia Albiaa, Anna Cabras, Douglas Teixeira Leffa, Catarina Manuel, Valeria Parlatini, Assia Riccioni, Christoph U. Correll, Paolo Fusar-Poli, Marco Solmi, Samuele Cortese
ImportanceRepresentation of race and ethnicity in randomized clinical trials (RCTs) is critical for understanding treatment efficacy across populations with different racial and ethnic backgrounds.ObjectiveTo examine race and ethnicity representation and reporting across RCTs of pharmacotherapies for mental disorders.Data SourcesPubMed (Medline), Embase (Ovid), APA PsycInfo, and Web of Science were
-
Cross-Species Framework for Emotional Well-Being and Brain Aging JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-07 F. Vankee Lin, Janine M. Simmons, Adam Turnbull, Yi Zuo, Yeates Conwell, Kuan Hong Wang
ImportanceEmotional well-being (EWB) is an emerging therapeutic target for managing and preventing symptoms associated with Alzheimer disease and related dementias (ADRD). However, more research is needed to establish causal inferences between brain changes, EWB, and behavioral changes observed in typical aging and ADRD.ObservationsThis article presents a framework for using a cross-species behavioral
-
Antipsychotic Acute-Phase Treatment in Individuals With and Without Recent Treatment JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-07 Lasse Brandt, Orestis Efthimiou, Spyridon Siafis, Johannes Schneider-Thoma, Heiner Stuke, Hakan Ayrilmaz, Alkomiet Hasan, Andreas Heinz, Stefan Gutwinski, John M. Kane, Stefan Leucht
ImportanceIt has been hypothesized that the association between acute-phase treatment with antipsychotic (vs placebo) and outcomes might be larger in individuals who were not recently treated compared to recently treated individuals. However, evidence is still lacking.ObjectiveTo compare the association between antipsychotic (vs placebo) acute-phase treatment and outcomes in individuals who were not
-
Biomedical Advances for Health Impacts of Nondisordered Drug Use. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-30 Boris Sabirzhanov,Leonardo M Angelone,Elena Koustova
-
Positive Emotion Dysregulation in Opioid Use Disorder and Normalization by Mindfulness-Oriented Recovery Enhancement JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-30 Eric L. Garland, Justin Hudak, Adam W. Hanley, Edward Bernat, Brett Froeliger
ImportanceIt remains unknown whether difficulties in positive emotion regulation (ER) drive opioid use disorder (OUD) and whether these difficulties may be remediated.ObjectiveTo test whether OUD is associated with attenuated positive ER and whether such positive emotion dysregulation may be treated by mindfulness-based intervention.Design, Setting, and ParticipantsIn this mechanistic substudy of a
-
Key Considerations in Mediation Analysis for Psychiatric Research. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-23 Zui C Narita,Mitsuhiro Miyashita,Toshi A Furukawa,Atsuhi Nishida
-
Distinct Convergent Brain Alterations in Sleep Disorders and Sleep Deprivation JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-23 Gerion M. Reimann, Alireza Hoseini, Mihrican Koçak, Melissa Beste, Vincent Küppers, Ivana Rosenzweig, David Elmenhorst, Gabriel Natan Pires, Angela R. Laird, Peter T. Fox, Kai Spiegelhalder, Kathrin Reetz, Simon B. Eickhoff, Veronika I. Müller, Masoud Tahmasian
ImportanceSleep disorders have different etiologies yet share some nocturnal and daytime symptoms, suggesting common neurobiological substrates; healthy individuals undergoing experimental sleep deprivation also report analogous daytime symptoms. However, brain similarities and differences between long-term sleep disorders and short-term sleep deprivation are unclear.ObjectiveTo investigate the shared
-
Understanding Placebo Mechanisms to Reduce Attrition in Psychiatric Trials. JAMA Psychiatry (IF 22.5) Pub Date : 2025-06-01 Nathan T M Huneke,Samuele Cortese,Marco Solmi
-
Cognitive Behavior Therapy for Mental Disorders in Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16 Pim Cuijpers, Mathias Harrer, Clara Miguel, Marketa Ciharova, Davide Papola, Djordje Basic, Cristina Botella, Ioana Cristea, Nino de Ponti, Tara Donker, Ellen Driessen, Pamela Franco, Irene Gómez-Gómez, Jessica Hamblen, Noelia Jiménez-Orenga, Eirini Karyotaki, Aaron Keshen, Jake Linardon, Emma Motrico, Minoo Matbouriahi, Olga M. Panagiotopoulou, Rory A. Pfund, Constantin Yves Plessen, Heleen Riper
ImportanceCognitive behavior therapy (CBT) is a first-line treatment for most mental disorders. However, no meta-analytic study has yet integrated the results of randomized clinical trials on CBT across different disorders, using uniform methodologies and providing a complete overview of the field.ObjectiveTo examine the effect sizes of CBT for 4 anxiety disorders, 2 eating disorders, major depression
-
Issues in Clinical Trial Design—Lessons From the FDA’s Rejection of MDMA JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16 Samuel T. Wilkinson, Gerard Sanacora
This Viewpoint explores potential justifications underlying the US Food and Drug Administration (FDA)’s rejection of methylenedioxymethamphetamine (MDMA) as a treatment for posttraumatic stress disorder, including lack of blinding and issues around the integrity of relevant clinical trials.
-
Negative Effects During Placebo Treatment JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-16 Tom Bschor, Josephine Unger, Lea Nagel, Guido Schwarzer, Christopher Baethge
ImportanceAnalyzing effects within placebo groups allows for transdiagnostic comparisons, as placebo is the only substance systematically studied across all major psychiatric diagnoses. Recently, the study team meta-analytically showed that improvement under placebo varies across major psychiatric diagnoses. However, comprehensive transdiagnostic comparisons of negative effects under placebo (nocebo
-
Lessons Learned From Drug Decriminalization Remedies in British Columbia. JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-14 John F Kelly
-
Automating the Addiction Behaviors Checklist for Problematic Opioid Use Identification JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09 Angus H. Chatham, Eli D. Bradley, Vanessa Troiani, Donielle L. Beiler, Parker Christy, Lori Schirle, Sandra Sanchez-Roige, David C. Samuels, Alvin D. Jeffery
ImportanceIndividuals whose chronic pain is managed with opioids are at high risk of developing an opioid use disorder. Electronic health records (EHR) allow large-scale studies to identify a continuum of problematic opioid use, including opioid use disorder. Traditionally, this is done through diagnostic codes, which are often unreliable and underused.ObjectiveTo determine whether regular expressions
-
Convergence of Cannabis and Psychosis on the Dopamine System JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09 Jessica Ahrens, Sabrina D. Ford, Betsy Schaefer, David Reese, Ali R. Khan, Philip Tibbo, Rachel Rabin, Clifford M. Cassidy, Lena Palaniyappan
ImportanceDespite evidence that individuals with a cannabis use disorder (CUD) are at elevated risk of psychosis and that the neurotransmitter dopamine has a role in psychosis, the mechanism linking cannabis use and psychosis remains unclear.ObjectiveTo use neuromelanin-sensitive magnetic resonance imaging (MRI), referred to as the neuromelanin-MRI signal, a practical, proxy measure of dopamine function
-
Clinician Suicide Risk Assessment for Prediction of Suicide Attempt in a Large Health Care System JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-09 Kate H. Bentley, Chris J. Kennedy, Pratik N. Khadse, Jasmin R. Brooks Stephens, Emily M. Madsen, Matthew J. Flics, Hyunjoon Lee, Jordan W. Smoller, Taylor A. Burke
ImportanceClinical practice guidelines recommend suicide risk screening and assessment across behavioral health settings. The predictive accuracy of real-world clinician assessments for stratifying patients by risk of future suicidal behavior, however, remains understudied.ObjectiveTo evaluate routine clinical suicide risk assessment for prospectively predicting suicide attempt.Design, Setting, and
-
Functional vs Structural Cortical Deficit Pattern Biomarkers for Major Depressive Disorder JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-04 Peter Kochunov, Bhim M. Adhikari, David Keator, Daniel Amen, Si Gao, Nicole R. Karcher, Demetrio Labate, Robert Azencott, Yewen Huang, Hussain Syed, Hongjie Ke, Paul M. Thompson, Danny J. J. Wang, Braxton D. Mitchell, Jessica A. Turner, Theo G.M. van Erp, Neda Jahanshad, Yizhou Ma, Xiaoming Du, William Burroughs, Shuo Chen, Tianzhou Ma, Jair C. Soares, L. Elliot Hong
ImportanceMajor depressive disorder (MDD) is a severe mental illness characterized more by functional rather than structural brain abnormalities. The pattern of regional homogeneity (ReHo) deficits in MDD may relate to underlying regional hypoperfusion. Capturing this functional deficit pattern provides a brain pattern–based biomarker for MDD that is linked to the underlying pathophysiology.ObjectiveTo
-
Esketamine Combined With SSRI or SNRI for Treatment-Resistant Depression JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-04 Antonio Del Casale, Sara Spirito, Jan Francesco Arena, Saskia Preissner, Marina Borro, Giovanna Gentile, Martina Nicole Modesti, Robert Preissner, Stefano Ferracuti, Maurizio Simmaco
ImportanceTreatment-resistant depression (TRD) remains a critical challenge in psychiatry, with limited effective options. Esketamine, a rapid-acting antidepressant, is usually combined with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), but comparative evidence of these combinations’ effectiveness in real-world settings is sparse.ObjectiveTo
-
Refining Social Determinants of Suicide Risk Research. JAMA Psychiatry (IF 22.5) Pub Date : 2025-06-01 Ping-I Lin,Nawar Nayeem,Erick Messias
-
Demographic Gaps and Digital Innovations in Therapy Trends. JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-01 Qiang Xie
-
Demographic Gaps and Digital Innovations in Therapy Trends-Reply. JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-01 Mark Olfson
-
Should Inflammation Be a Specifier for Major Depression in the DSM-6? JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02 Manish K. Jha, Marion Leboyer, Carmine M. Pariante, Andrew H. Miller
This Viewpoint discusses the opportunity to include inflammatory biomarkers as specifiers for major depression in the upcoming Sixth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-6).
-
Genetic Confounding in the Association Between Traumatic Brain Injury and Mental Disorder or Suicide JAMA Psychiatry (IF 22.5) Pub Date : 2025-04-02 Søren Dinesen Østergaard, Jessica Mundy, Alisha Silvia Mercedes Hall, Katherine L. Musliner
ImportanceTraumatic brain injury is common and occurs across all ages. Observational studies have shown that traumatic brain injury is associated with a wide range of mental disorders and suicide. Whether these associations represent a causal effect is, however, difficult to establish, and confounding by genetic liability for mental disorder may play a substantial role.ObjectiveTo investigate whether
-
Caring for Patients With Severe Anorexia Nervosa—A Capacity Evaluation Cannot Save Us JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26 Emily G. Holmes, Jane A. Hartsock, Amy S. Martin
This Viewpoint discusses assessing decision-making capacity in patients with severe anorexia nervosa and why a multidisciplinary approach is preferred.
-
Prescription Stimulant Prescribing, Nonmedical Use, and Shortages JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26 Joshua P. Rising, Robert M. Califf
This Viewpoint discusses developing better evidence about appropriate use of stimulants, understanding and reducing nonmedical use of these medications, and responding to shortages.
-
Effective Components of Collaborative Care for Depression in Primary Care: An Individual Participant Data Meta-Analysis. JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-26 Hannah Schillok,Jochen Gensichen,Maria Panagioti,Jane Gunn,Lukas Junker,Karoline Lukaschek,Caroline Jung-Sievers,Philipp Sterner,Lukas Kaupe,Tobias Dreischulte,Mohammed K Ali,Enric Aragonès,David B Bekelman,Birgit Herbeck Belnap,Robert M Carney,Lydia A Chwastiak,Peter A Coventry,Karina W Davidson,Maria L Ekstrand,Alison Flehr,Susan Fletcher,Lars P Hölzel,Klaas Huijbregts,Viswanathan Mohan,Vikram Patel
Importance Collaborative care is a multicomponent intervention for patients with chronic disease in primary care. Previous meta-analyses have proven the effectiveness of collaborative care for depression; however, individual participant data (IPD) are needed to identify which components of the intervention are the principal drivers of this effect. Objective To assess which components of collaborative
-
Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-19 Pouya Ebrahimi, Juan Carlos Batlle, Aryan Ayati, M. Haisum Maqsood, Clarine Long, Constantine Tarabanis, Natalie McGowan, David T. Liebers, Gregory Laynor, Kaveh Hosseini, Sean P. Heffron
ImportanceBariatric surgery, once the criterion standard in obesity treatment, has a small but concerning association with increased suicidality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), originally developed to treat diabetes, now provide substantial efficacy in the treatment of obesity. However, concerns of risk of suicidality with these medicines have been raised.ObjectiveTo evaluate
-
Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-19 Beth Han, Christopher M. Jones, Nora D. Volkow, S. Michaela Rikard, Deborah Dowell, Emily B. Einstein, Gery P. Guy, Naomi Tomoyasu, Jean Ko, Grant Baldwin, Yngvild Olsen, Wilson M. Compton
ImportanceStimulants are increasingly prescribed for US adults. Whether such prescribing is associated with misuse and prescription stimulant use disorder (PSUD) is less understood.ObjectivesTo examine (1) sex- and age-specific trends in the number of persons dispensed stimulants and trends in dispensed prescription stimulants by prescriber specialty in 2019 through 2022; (2) prevalence of misuse and
-
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-19 Lorenz Mueller, Joyce Santos de Jesus, Yasmin Schmid, Felix Müller, Anna Becker, Aaron Klaiber, Isabelle Straumann, Dino Luethi, Eline C. H. M. Haijen, Petra P. M. Hurks, Kim P. C. Kuypers, Matthias E. Liechti
ImportanceMicrodosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disorders, including attention-deficit/hyperactivity disorder (ADHD). However, LSD’s efficacy in reducing ADHD symptoms remains unknown.ObjectiveTo determine the safety and efficacy of repeated low doses of LSD in reducing ADHD symptoms compared with
-
Addressing the Double Bind of Women's Anger After Trauma. JAMA Psychiatry (IF 22.5) Pub Date : 2025-05-01 Olivia Metcalf,David Forbes
-
Maternal Inflammatory Proteins in Pregnancy and Neurodevelopmental Disorders at Age 10 Years JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-12 Tingting Wang, Parisa Mohammadzadeh, Jens Richardt Møllegaard Jepsen, Jonathan Thorsen, Julie Bøjstrup Rosenberg, Cecilie Koldbæk Lemvigh, Nicklas Brustad, Liang Chen, Mina Ali, Rebecca Vinding, Casper-Emil Tingskov Pedersen, María Hernández-Lorca, Birgitte Fagerlund, Birte Y. Glenthøj, Niels Bilenberg, Jakob Stokholm, Klaus Bønnelykke, Bo Chawes, Bjørn H. Ebdrup
IMPORTANCEMaternal inflammation during pregnancy has been associated with an increased risk of neurodevelopmental disorders (NDDs), such as attention-deficit/hyperactivity disorder (ADHD) and autism, and cognitive deficits in early childhood. However, little is known about the contributions of a wider range of inflammatory proteins to this risk.OBJECTIVETo determine whether maternal inflammatory proteins
-
Circulating Blood-Based Proteins in Psychopathology and Cognition JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-12 Upasana Bhattacharyya, Jibin John, Max Lam, Jonah Fisher, Benjamin Sun, Denis Baird, Stephen Burgess, Chia-Yen Chen, Todd Lencz
ImportancePeripheral (blood-based) biomarkers for psychiatric illness could benefit diagnosis and treatment, but research to date has typically been low throughput, and traditional case-control studies are subject to potential confounds of treatment and other exposures. Large-scale 2-sample mendelian randomization (MR) can examine the potentially causal impact of circulating proteins on neuropsychiatric
-
Expectancy Effects, Failure of Blinding Integrity, and Placebo Response in Trials of Treatments for Psychiatric Disorders JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-12 Nathan T. M. Huneke, Guilherme Fusetto Veronesi, Matthew Garner, David S. Baldwin, Samuele Cortese
ImportanceExpectancy effects are significant confounding factors in psychiatric randomized clinical trials (RCTs), potentially affecting the interpretation of study results. This narrative review is the first, to our knowledge, to explore the relationship between expectancy effects, compromised blinding integrity, and the effects of active treatment/placebo in psychiatric RCTs. Additionally, we present
-
Differences in Blood Leukocyte Subpopulations in Schizophrenia JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05 Leon Dudeck, Madeleine Nussbaumer, Thomas Nickl-Jockschat, Paul C. Guest, Henrik Dobrowolny, Gabriela Meyer-Lotz, Zhongming Zhao, Roland Jacobs, Kolja Schiltz, Brisa S. Fernandes, Johann Steiner
ImportanceThis study aims to provide robust evidence to support or challenge the immune hypothesis of schizophrenia.ObjectiveTo conduct a meta-analysis of reports on blood leukocyte subpopulations in schizophrenia vs healthy controls, examining disease- and treatment-related differences as well as potential confounders.Data SourcesSystematic database search for English and non-English peer-reviewed
-
Sports Gambling and Drinking Behaviors Over Time JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05 Joshua B. Grubbs, Alexander J. Connolly, Scott Graupensperger, Hyoun S. Kim, Shane W. Kraus
ImportanceSports gambling has become one of the most accessible forms of gambling in the United States, and recent research suggests that sports gambling coupled with frequent alcohol use may have deleterious health consequences.ObjectiveTo examine the trajectories of sports gambling frequency and alcohol-related problems over time and the associations between these trajectories.Design, Setting, and
-
Evidence-Based Practicing in Mental Health JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05 Benjamin G. Druss, Nev Jones
This Viewpoint explores the shift from the process-oriented concept of evidence-based practicing toward the development and distribution of evidence-based practices within the sphere of mental health care.
-
Accelerated Theta-Burst Stimulation for Treatment-Resistant Depression JAMA Psychiatry (IF 22.5) Pub Date : 2025-03-05 Matheus Rassi F. Ramos, Stephan Goerigk, Valquiria Aparecida da Silva, Beatriz Araújo Cavendish, Bianca Silva Pinto, Cássio Henrique Gomide Papa, João Vitor Resende, Izio Klein, Adriana Munhoz Carneiro, Juliana Pereira de Sousa, Kallene Summer Moreira Vidal, Leandro da Costa Lane Valiengo, Lais B. Razza, Luana Marotti Aparício, Lisiane Martins, Lucas Borrione, Mariana Batista, Natasha Kouvalesk Moran
ImportanceIntermittent theta-burst stimulation (iTBS) is an established treatment for treatment-resistant depression (TRD). Sessions conducted more than once daily (ie, accelerated TBS [aTBS]) may enhance antidepressant effects. However, evidence is limited to small trials, and protocols are time-consuming and can require neuroimaging-based targeting.ObjectiveTo evaluate the efficacy and safety of
-
An Approach to Providing Timely Mental Health Services to Diverse Youth Populations JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-26 Srividya N. Iyer, Patricia Boksa, Ridha Joober, Jai Shah, Rebecca Fuhrer, Neil Andersson, Shalini Lal, Giuseppe D’Andrea, Nora Morrison, Valerie Noel, Daniel Rabouin, Tovah Cowan, Kathleen MacDonald, Mary Anne Levasseur, Feodor Poukhovski-Sheremetyev, Amal Abdel-Baki, Lacey Augustine, Kevin Friese, Isabelle Godin, Katherine Hay, Daphne Hutt-MacLeod, Vickie Plourde, Norma Rabbitskin, Paula Reaume-Zimmer
ImportanceAccessing mental health care is challenging for youths, especially those facing intersectional disadvantages, but whether enhancing youth services increases reach and timeliness has rarely been investigated. ACCESS Open Minds (ACCESS-OM) transformed services at urban, rural, and Indigenous sites in Canada using 5 principles (early identification, rapid access, appropriate care, no age-based
-
Genetic Correlates of Treatment-Resistant Depression JAMA Psychiatry (IF 22.5) Pub Date : 2025-02-26 Bohan Xu, Katherine L. Forthman, Rayus Kuplicki, Jonathan Ahern, Robert Loughnan, Firas Naber, Wesley K. Thompson, Charles B. Nemeroff, Martin P. Paulus, Chun Chieh Fan
ImportanceTreatment-resistant depression (TRD) is a major challenge in mental health, affecting a significant number of patients and leading to considerable burdens. The etiological factors contributing to TRD are complex and not fully understood.ObjectiveTo investigate the genetic factors associated with TRD using polygenic scores (PGS) across various traits and explore their potential role in the